Core Viewpoint - Adtalem Global Education is rebranding to Covista, signifying a major transformation aimed at becoming the largest healthcare educator in the U.S. and a vital part of the healthcare workforce pipeline [1] Company Summary - The rebranding reflects a four-year transformation process undertaken by the company [1] - Covista will begin trading under the ticker symbol CVSA on the New York Stock Exchange starting February 24, 2026 [1] - The name change is described as more than just a rebrand; it acknowledges the company's achievements and the challenges it aims to address in the healthcare sector [1]

The Zacks Schools industry enters 2026 facing notable headwinds, including a shrinking traditional student base, intensifying competition from public and nonprofit institutions and continued affordability pressures. Regulatory oversight around student outcomes, financial transparency and federal aid eligibility is tightening, increasing compliance costs and execution risk, particularly for career-focused providers. At the same time, rising marketing, labor and technology expenses are weighing on margins, wh ...

Adtalem Global Education Inc. (ATGE) Stock Analysis: A Closer Look at Recent Performance and Growth PotentialAdtalem Global Education Inc. (NYSE: ATGE) is a leading provider of educational services, offering a wide range of programs across various fields such as healthcare, business, and technology. The company operates several institutions, including Chamberlain University and Ross University School of Medicine. Adtalem competes with other educational service providers like Grand Canyon Education and Stray ...

Core Viewpoint - The article highlights Adtalem Global Education (ATGE) as a promising growth stock, supported by its favorable Growth Score and Zacks Rank, indicating strong potential for outperformance in the market [2][11]. Earnings Growth - Adtalem has a historical EPS growth rate of 22.4%, with projected EPS growth of 18% for the current year, significantly surpassing the industry average of 11.5% [5]. Asset Utilization Ratio - The company has an asset utilization ratio (sales-to-total-assets ratio) of 0.69, indicating it generates $0.69 in sales for every dollar in assets, which is higher than the industry average of 0.68, showcasing better efficiency [6]. Sales Growth - Adtalem's sales are expected to grow by 7.6% this year, compared to the industry average of 6.7%, indicating a strong sales growth outlook [7]. Earnings Estimate Revisions - The current-year earnings estimates for Adtalem have been revised upward, with the Zacks Consensus Estimate increasing by 0.3% over the past month, reflecting positive sentiment [9]. Overall Positioning - With a Zacks Rank of 2 and a Growth Score of A, Adtalem is well-positioned for potential outperformance, making it an attractive option for growth investors [11].

Adtalem Global Education (ATGE) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system ...

Core Viewpoint - Adtalem Global Education (ATGE) shows potential for significant upside, with a mean price target of $158.25 indicating a 46.8% increase from its current price of $107.78 [1] Price Targets - The average price target for ATGE ranges from a low of $125.00 to a high of $175.00, with a standard deviation of $22.71, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 16% increase, while the highest suggests a 62.4% upside [2] Analyst Sentiment - Analysts exhibit strong agreement on ATGE's ability to report better earnings than previously predicted, which supports the expectation of stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.3%, with one estimate moving higher and no negative revisions [12] Zacks Rank - ATGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Price Movement Implications - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Adtalem Global Education (ATGE) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $1.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +11.21%. A quarter ago, it was expected that this for-profit education company would post earnings of $1.57 per share when it actually produced earnings of $1.75, delivering a surprise of +11.46%.Over the ...

Financial Data and Key Metrics Changes - Total revenue increased by 12.4% to $503.4 million, driven by all three segments [17] - Adjusted EBITDA grew to $154.9 million, up 23.9% compared to the prior year [18] - Adjusted earnings per share rose to $2.43, a 34.3% increase year-over-year [19] - Operating cash flow generation for the trailing twelve months was $428 million, up $146 million from the previous year [20] Business Line Data and Key Metrics Changes - Chamberlain reported revenue of $183.8 million, a 1.6% increase, but total student enrollment declined by 1% [22] - Walden's revenue increased by 27% to $217.6 million, with total student enrollment up 13% [23] - Medical and Veterinary segment revenue was $102 million, a 6.9% increase, with adjusted EBITDA rising by 17.6% [25] Market Data and Key Metrics Changes - Total enrollment grew over 6% to 97,000 students, marking the tenth consecutive quarter of enrollment growth [4][7] - Chamberlain's pre-licensure BSN programs have seen growth for 14 consecutive quarters, while post-licensure programs faced declines [22] - Walden's growth was particularly strong in behavioral sciences and nursing programs [32] Company Strategy and Development Direction - The company is focused on addressing the healthcare workforce crisis by expanding capacity and creating new revenue streams [7] - A disciplined, returns-focused approach to capital allocation is being maintained, with $165 million deployed for share repurchases [4] - The upcoming Investor Day will outline a multi-year growth framework [7][47] Management's Comments on Operating Environment and Future Outlook - The healthcare workforce crisis is intensifying, with significant gaps expected to deepen, particularly in rural and underserved areas [6][7] - Management remains confident in achieving full-year revenue guidance of 6%-8.5% growth and has raised adjusted EPS guidance to 17%-20% growth [4][27] - The company expects application growth at Chamberlain to translate into future enrollment growth [27] Other Important Information - The company has approximately $728 million remaining on its current share repurchase authorization [4] - Adjusted EBITDA margin expanded by 290 basis points to 30.8% [18] - The one-week academic calendar shift contributed an additional $18 million in revenue for Walden in Q2 [17][26] Q&A Session Summary Question: Can you provide insights on Walden's growth and market share? - Management noted that growth is consistent across programs, particularly in behavioral sciences and nursing, indicating potential market share gains [32] Question: What is the status of the partnership with Sallie Mae regarding loan caps? - Management confirmed they are working on definitive documentation for the partnership and are optimistic about its implications for the portfolio [33] Question: Can you elaborate on Chamberlain's enrollment trends and lead times? - Management acknowledged recent improvements in application volumes and expressed confidence in returning to positive enrollment growth by the fall cycle [39][40] Question: What factors could lead to exceeding the high end of revenue guidance? - Management indicated that quicker recovery at Chamberlain and acceleration in the Med Vet segment could contribute to exceeding guidance [42]

Financial Data and Key Metrics Changes - Revenue in Q2 increased by 12.4% to $503.4 million, driven by all three segments, with Walden contributing significantly due to a one-week academic calendar shift [17][26] - Adjusted EBITDA grew to $154.9 million, up 23.9% year-over-year, with an adjusted EBITDA margin of 30.8%, expanding 290 basis points from last year [18][25] - Adjusted net income for the quarter was $87.9 million, a 26.7% increase compared to last year, with adjusted earnings per share rising to $2.43, a 34.3% increase [19][20] Business Line Data and Key Metrics Changes - Chamberlain reported revenue of $183.8 million, a 1.6% increase, but total student enrollment declined by 1% [22] - Walden's revenue reached $217.6 million, a 27% increase, with total student enrollment up 13% [23] - The Medical and Veterinary segment generated $102 million in revenue, a 6.9% increase, with adjusted EBITDA increasing by 17.6% [24][25] Market Data and Key Metrics Changes - Total enrollment across the company grew over 6% to 97,000 students, with Walden achieving record total enrollments of 52,400 students [7][11] - Chamberlain's pre-licensure BSN programs have grown for 14 consecutive quarters, while post-licensure programs faced declines [22][10] Company Strategy and Development Direction - The company is focused on addressing the healthcare workforce crisis by expanding capacity and creating new revenue streams [6][7] - A disciplined, returns-focused approach to capital allocation is being maintained, with $165 million deployed to share repurchases [4][20] - The upcoming Investor Day will outline a multi-year growth framework and capacity expansion plans [7][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year revenue guidance of 6%-8.5% growth and raised adjusted EPS guidance to 17%-20% growth [4][27] - The healthcare workforce crisis is intensifying, creating opportunities for the company to expand its role in healthcare education [6][7] - Management noted that application volumes for nursing programs are up, indicating potential future enrollment growth [10][39] Other Important Information - The company repurchased 1.7 million shares at an average price of $95, completing a prior $150 million authorization and announcing a new $750 million authorization [20] - The trailing twelve months operating cash flow generation reached $428 million, up $146 million year-over-year [20] Q&A Session Summary Question: Update on Walden's growth and market share - Management noted balanced growth across programs, particularly in behavioral sciences and nursing, indicating potential market share gains [32] Question: Regulatory changes and partnership with Sallie Mae - Management confirmed ongoing work with Sallie Mae on documentation for a partnership to provide loan dollars, particularly for the medical and veterinary segment [33] Question: Chamberlain's enrollment and marketing effectiveness - Management discussed improvements in application volumes and marketing effectiveness, expressing confidence in a positive enrollment trajectory for the fall cycle [39][40]

Adtalem Global Education (NYSE:ATGE) Q2 2026 Earnings call January 28, 2026 05:00 PM ET Speaker4...Welcome to the Adtalem Global Education second quarter 2026 earnings. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jay S ...